Nanjing Vazyme Biotech Co., Ltd. (688105.SS)
CNY 24.46
(0.62%)
CNY 24.46
(0.62%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.01 Billion CNY | -9.75% |
| 2022 | 1.22 Billion CNY | 69.33% |
| 2021 | 721.36 Million CNY | 76.75% |
| 2020 | 408.11 Million CNY | 105.16% |
| 2019 | 198.93 Million CNY | 44.66% |
| 2018 | 137.51 Million CNY | 52.52% |
| 2017 | 90.16 Million CNY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 238 Million CNY | -32.45% |
| 2024 Q2 | 226.62 Million CNY | -4.78% |
| 2024 Q3 | 243.98 Million CNY | 7.54% |
| 2023 Q1 | 241.22 Million CNY | -42.96% |
| 2023 FY | 1.1 Billion CNY | -9.75% |
| 2023 Q4 | 352.32 Million CNY | 67.63% |
| 2023 Q3 | 210.18 Million CNY | -19.75% |
| 2023 Q2 | 261.89 Million CNY | 8.57% |
| 2022 Q3 | 325.77 Million CNY | 24.25% |
| 2022 Q2 | 262.19 Million CNY | 24.47% |
| 2022 Q1 | 210.65 Million CNY | -17.0% |
| 2022 FY | 1.22 Billion CNY | 69.33% |
| 2022 Q4 | 422.88 Million CNY | 29.81% |
| 2021 Q3 | 210.03 Million CNY | 231.75% |
| 2021 Q1 | -109.16 Million CNY | -182.22% |
| 2021 Q2 | -159.41 Million CNY | -46.03% |
| 2021 FY | 721.36 Million CNY | 76.75% |
| 2021 Q4 | 253.78 Million CNY | 20.83% |
| 2020 Q1 | -60.16 Million CNY | 0.0% |
| 2020 FY | 408.11 Million CNY | 105.16% |
| 2020 Q3 | 107.71 Million CNY | 177.28% |
| 2020 Q2 | -139.37 Million CNY | -131.64% |
| 2020 Q4 | 132.77 Million CNY | 23.27% |
| 2019 FY | 198.93 Million CNY | 44.66% |
| 2018 FY | 137.51 Million CNY | 52.52% |
| 2017 FY | 90.16 Million CNY | 0.0% |